Company Overview
Cosmos Health Inc. operates within the healthcare sector, specifically focusing on the medical distribution industry, where it manufactures, develops, and trades branded nutraceutical products across a diverse international footprint including Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company's product portfolio is extensive, encompassing prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, and cosmetics. This business model positions Cosmos Health as a specialized distributor and developer of health-related goods rather than a traditional generic pharmaceutical manufacturer. The company's scale is defined by a market capitalization of $12.13M and an annual revenue of $59.79M, supported by a workforce of 149 employees. These valuation and revenue figures indicate that Cosmos Health operates as a small-cap entity with a relatively modest revenue base compared to large-scale pharmaceutical distributors, suggesting a position that is highly sensitive to market fluctuations and niche market performance.
Financial Health
Cosmos Health Inc. reported revenue of $59.79M over the trailing twelve months, yet this top-line growth is not reflected in profitability, as the company recorded a net income of $-18,542,138 and an EBITDA of $-12,621,250. The significant gap between the $59.79M in revenue and the net loss of approximately $18.5M reveals a highly leveraged cost structure where operating expenses and cost of goods sold consume a substantial portion of every dollar generated. Furthermore, the company generated free cash flow of $-5,310,300, indicating a lack of financial flexibility to fund operations or investments without external capital or significant deleveraging efforts. This negative cash flow suggests that the business model currently consumes cash reserves at a rate that requires careful monitoring of liquidity sources. The company's profitability metrics are further eroded by a gross margin of 11.4%, an operating margin of -10.6%, and a profit margin of -31.0%, which collectively indicate that the company is struggling to cover its fixed costs and overheads despite selling products. On the balance sheet, Cosmos Health holds $922,619 in cash against $21.07M in debt, resulting in a debt-to-equity ratio of 91.08, which characterizes the balance sheet as highly leveraged rather than conservative. Liquidity is constrained by a current ratio of 0.99, which indicates that the company's current assets are insufficient to cover its current liabilities without relying on external financing or asset sales. Finally, the return on equity stands at -63.8% and the return on assets is -13.0%, metrics that reveal that management is currently destroying shareholder value and utilizing assets inefficiently rather than generating positive returns.
Valuation Assessment
The valuation of Cosmos Health Inc. presents a complex picture with a trailing P/E ratio of N/A due to losses, while the forward P/E is listed at -2.95, implying that the market is pricing in a potential recovery or restructuring rather than current earnings generation. The price-to-book ratio is 0.45, indicating that the market values the company at less than half of its book value, which suggests a deep discount relative to its net asset position or a market expectation of significant future impairment. Alternative valuation metrics such as the price-to-sales ratio of 0.20 and an EV/EBITDA of -2.50 further highlight that the stock is being valued based on sales multiples rather than earnings power, a common characteristic of distressed or turnaround small-cap stocks. Regarding price action, the stock has a 52-week high of $1.32 and a 52-week low of $0.28, meaning the current trading price sits significantly below the recent highs, reflecting the negative earnings trajectory and high volatility associated with the stock. The beta value is 4.49, which indicates that the stock's price volatility is nearly four and a half times greater than that of the broader market, making it a highly speculative instrument subject to extreme swings in investor sentiment.
Growth & Income
Cosmos Health Inc. demonstrated a revenue growth rate of 37.9% year-over-year, whereas earnings growth is N/A, indicating that the company is growing its top line faster than its ability to generate profit, a disparity often seen in early-stage or restructuring businesses. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that the company retains all available earnings to reinvest into growth initiatives or to service its heavy debt load rather than distributing income to shareholders. This approach to capital allocation prioritizes operational expansion or balance sheet repair over providing immediate income returns to investors. Consequently, the overall growth and income profile of Cosmos Health is defined by aggressive revenue expansion coupled with significant losses and zero dividend income, positioning the stock as a pure play on future operational success rather than current profitability or yield.